PDGFRB and hepatocellular carcinoma: Sorafenib is the only drug currently approved for advanced Hepatocellular Carcinoma (HCC) and acts by blocking Vascular Endotelial Growth Factor Receptor 2 (VEGFR2), Platelet Derived Growth Factor Receptor (PDGFR), Raf-1, B-Raf and c-kit among others [9].